» Articles » PMID: 23909438

Nogo-A Couples with Apg-1 Through Interaction and Co-ordinate Expression Under Hypoxic and Oxidative Stress

Overview
Journal Biochem J
Specialty Biochemistry
Date 2013 Aug 6
PMID 23909438
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Nogo-A is the largest isoform of the Nogo/RTN4 (reticulon 4) proteins and has been characterized as a major myelin-associated inhibitor of regenerative nerve growth in the adult CNS (central nervous system). Apart from the myelin sheath, Nogo-A is expressed at high levels in principal neurons of the CNS. The specificity of Nogo-A resides in its central domain, NiG. We identified Apg-1, a member of the stress-induced Hsp110 (heat-shock protein of 110 kDa) family, as a novel interactor of NiG/Nogo-A. The interaction is selective because Apg-1 interacts with Nogo-A/RTN4-A, but not with RTN1-A, the closest paralogue of Nogo-A. Conversely, Nogo-A binds to Apg-1, but not to Apg-2 or Hsp105, two other members of the Hsp110 family. We characterized the Nogo-A-Apg-1 interaction by affinity precipitation, co-immunoprecipitation and proximity ligation assay, using primary hippocampal neurons derived from Nogo-deficient mice. Under conditions of hypoxic and oxidative stress we found that Nogo-A and Apg-1 were tightly co-regulated in hippocampal neurons. Although both proteins were up-regulated under hypoxic conditions, their expression levels were reduced upon the addition of hydrogen peroxide. Taken together, we suggest that Nogo-A is closely involved in the neuronal response to hypoxic and oxidative stress, an observation that may be of relevance not only in stroke-induced ischaemia, but also in neuroblastoma formation.

Citing Articles

The Overexpression of RTN4 Significantly Associated With an Unfavourable Prognosis in Patients With Lower-Grade Gliomas.

Feng J, Zhao L, Chen H, Lin J, Shang M, Xu B J Cell Mol Med. 2025; 29(4):e70418.

PMID: 39969103 PMC: 11837034. DOI: 10.1111/jcmm.70418.


Amino-terminal proteolytic fragment of the axon growth inhibitor Nogo-A (Rtn4A) is upregulated by injury and promotes axon regeneration.

Sekine Y, Wang X, Kikkawa K, Honda S, Strittmatter S J Biol Chem. 2023; 299(10):105232.

PMID: 37690690 PMC: 10622843. DOI: 10.1016/j.jbc.2023.105232.


New insights in ferroptosis: Potential therapeutic targets for the treatment of ischemic stroke.

Wei Z, Xie Y, Wei M, Zhao H, Ren K, Feng Q Front Pharmacol. 2022; 13:1020918.

PMID: 36425577 PMC: 9679292. DOI: 10.3389/fphar.2022.1020918.


Nogo-A/NgR signaling regulates stemness in cancer stem-like cells derived from U87MG glioblastoma cells.

Ai C, Zhou Y, Pu K, Yang Y, Zhou Y Oncol Lett. 2022; 24(1):230.

PMID: 35720478 PMC: 9185138. DOI: 10.3892/ol.2022.13351.


Could the Heat Shock Proteins 70 Family Members Exacerbate the Immune Response in Multiple Sclerosis? An in Silico Study.

Chiricosta L, Gugliandolo A, Bramanti P, Mazzon E Genes (Basel). 2020; 11(6).

PMID: 32503176 PMC: 7348765. DOI: 10.3390/genes11060615.


References
1.
Oertle T, Schwab M . Nogo and its paRTNers. Trends Cell Biol. 2003; 13(4):187-94. DOI: 10.1016/s0962-8924(03)00035-7. View

2.
Xue J, Fukuyama H, Nonoguchi K, Kaneko Y, Kido T, Fukumoto M . Induction of Apg-1, a member of the heat shock protein 110 family, following transient forebrain ischemia in the rat brain. Biochem Biophys Res Commun. 1998; 247(3):796-801. DOI: 10.1006/bbrc.1998.8894. View

3.
Schweigreiter R, Bandtlow C . Nogo in the injured spinal cord. J Neurotrauma. 2006; 23(3-4):384-96. DOI: 10.1089/neu.2006.23.384. View

4.
van de Velde H, Roebroek A, van Leeuwen F, Van de Ven W . Molecular analysis of expression in rat brain of NSP-A, a novel neuroendocrine-specific protein of the endoplasmic reticulum. Brain Res Mol Brain Res. 1994; 23(1-2):81-92. DOI: 10.1016/0169-328x(94)90214-3. View

5.
Yoneyama M, Iwamoto N, Nagashima R, Sugiyama C, Kawada K, Kuramoto N . Altered expression of heat shock protein 110 family members in mouse hippocampal neurons following trimethyltin treatment in vivo and in vitro. Neuropharmacology. 2008; 55(5):693-703. DOI: 10.1016/j.neuropharm.2008.06.009. View